Sun Pharma reported a strong financial performance for the fourth quarter of FY26, with Sun Pharma Q4 revenue rising 13.6 per cent to Rs. 14,560 crore and Sun Pharma net profit jumping 26.2 per cent to Rs. 2,714 crore, reflecting healthy growt...
India’s heatwave crisis is turning into a public health emergency, with rising heatstroke deaths, underreported mortality, and growing strain on healthcare systems.
New clinical review validates capsaicin 0.075% for diabetic neuropathy pain relief, offering targeted, localized therapy with improved patient comfort and safety.
Regeneron’s Hyderabad GCC highlights India’s growing role in global biopharma R&D. The move signals a shift beyond cost arbitrage toward high-value capabilities in AI, clinical trials, and data-driven drug development.
Patent exclusivity expiry of $200–300B drugs is reshaping India’s pharma logistics. Rising generics, biosimilars, and cold-chain demand are driving investments in air cargo, ports, and compliant supply chains.
Moderna and Merck melanoma combo cuts spread risk by 59% in 5-year study. Personalized cancer vaccine with Keytruda shows strong survival gains and recurrence prevention.
Indian drugmakers deepen US market focus despite export decline in FY26, driven by pricing pressure, generics slowdown, and shift toward specialty drugs and local manufacturing.
Hidden thyroid risk in young India crosses 50%, study finds. Experts flag subclinical thyroid disorders, delayed diagnosis, and rising need for preventive screening.
India emerges as Novo Nordisk’s global launch engine, powering AI-led drug development, faster approvals, and stronger Wegovy data amid rising competition in obesity drugs.
A rare 1-in-9M brain disorder was diagnosed in a pregnant woman after migraine misdiagnosis, highlighting timely neurosurgery and expert care.